BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
ascopubs.org

Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras

Expanded Access and Right To Try Requests: The Community Oncologist's Experience We hypothesized that because of availability of ICIs, systemic therapy use in the last 30 days of life (DOL) would have ...
News Medical

Combination of radiation and systemic therapy can prolong survival for advanced liver cancer patients

Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.